We have developed different in vitro, ex vivo and in vivo assays to measure the angiogenic potency of the cultured ADRCs, and we have found a new way to culture the cells while keeping the biological activity. Industry and biotech partners will help to further develop the ‘Blue Cells’ as a product to obtain EMA/FDA approval and reach the market.